





































- izinischen Fachgesellschaften. Das Fibromyalgiesyndrom. Definition, Klassifikation, klinische Diagnose und Prognose (Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis). *Schmerz*. 2012; 26: 247-258. [In German].
28. Häuser W, Eich W, Herrmann M, et al. Fibromyalgia syndrome: classification, diagnosis, and treatment. *Dtsch Arztebl Int* 2009; 106: 383-391.
29. Direzione Generale Cura della Persona, Salute e Welfare regionale, dell'Agenzia Sanitaria e Sociale regionale, delle Aziende Sanitarie della Emilia-Romagna. Linee di Indirizzo per la diagnosi e il trattamento della Fibromialgia; 2018. Available from: <https://salute.regione.emilia-romagna.it/normativa-e-documentazione/linee-di-indirizzo/fibromialgia>
30. Salaffi F, Farah S, Di Carlo M, et al. Italian Society of Rheumatology (SIR) and Ministero della Salute - Direzione Generale della Programmazione Sanitaria, Roma, Italy. The Italian Fibromyalgia Registry: a new way of using routine real-world data concerning patient-reported disease status in healthcare research and clinical practice. *Clin Exp Rheumatol*. 2020; 38 (Suppl.) 123: 65-71.
31. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Semin Arthritis Rheum*. 2016; 46: 319-329.
32. Salaffi F, Di Carlo M, Farah S, et al. Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Scale. *Rheumatology (Oxford)* 2020 Mar 24.
33. Grayston R, Czanner G, Elhaddad M, et al. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. *Semin Arthritis Rheum*. 2019; 48: 933-940.
34. Santos J, Alarcão J, Fareleira F, et al. Tapentadol for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*. 2015; (5): CD009923.
35. Littlejohn GO, Guymer EK, Ngian GS. Is there a role for opioids in the treatment of fibromyalgia? *Pain Manag*. 2016; 6: 347-355.
36. Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. *Cochrane Database Syst Rev*. 2016; 9: CD011790.
37. Sarzi-Puttini P, Ablin J, Trabelsi A, et al. Cannabinoids in the treatment of rheumatic diseases: Pros and cons. *Autoimmun Rev*. 2019; 18: 102409.
38. Sarzi-Puttini P, Batticciotto A, Atzeni F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? *Expert Rev Clin Immunol*. 2019; 15: 1019-1032.
39. Giorgi V, Bongiovanni S, Atzeni F, et al. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. *Clin Exp Rheumatol*. 2020; 38 Suppl 123: 53-59.
40. Pérez-Fernández MR, Gavvo-Ayuso N, Martínez-Reglero C, et al. Efficacy of baths with mineral-medicinal water in patients with fibromyalgia: a randomized clinical trial. *Int J Biometeorol*. 2019; 63: 1161-1170.
41. Bazzichi L, Delle Y, Rossi A, et al. A multidisciplinary approach to study the effects of balneo therapy and mud-bath therapy treatment on fibromyalgia. *Clin Exp Rheumatol*. 2019; 37: S111-120.
42. Andrade A, Hech Dominski F, Mendes Sieczkowska S. What we already know about the effects of exercise in patients with fibromyalgia: An umbrella review. *Semin Arthritis Rheum*. 2020; 50: 1465-1480.
43. Salaffi F, Bazzichi L, Atzeni F, et al. Characterization and definition of disease severity status in fibromyalgia: results from a cross-sectional survey of 2,339 Italian people. *Rheumatology (Oxford)* 2021; 60: 728-736.
44. Sarzi-Puttini P, Batticciotto A, Atzeni F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? *Expert Rev Clin Immunol*. 2019; 15: 1019-1032.